Promoted Content
Promoted Content

Find Novel Oncology Drugs in Preclinical Development in GERMANY

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): CTL-002

            Therapeutic Area: Oncology Product Name: CTL-002

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Vesalius Biocapital III

            Deal Size: $61.0 million Upfront Cash: Undisclosed

            Deal Type: Series B Financing November 10, 2020

            Details:

            CatalYm’s lead molecule CTL-002 was specifically designed to neutralize a tumor-produced protein called GDF-15. CTL-002 addresses three of the tumor’s immune suppressive mechanisms all involving the inhibitory effect of GDF-15 on the immunostimulatory LFA-1/ICAM-1 interaction.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): IMA401

            Therapeutic Area: Oncology Product Name: IMA401

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 29, 2020

            Details:

            IMA401 is the first product candidate from Immatics’ TCR Bispecifics pipeline. The IMA401 target, an HLA-A*02-bound peptide derived both from MAGEA4 and MAGEA8, shows >5-fold higher target peptide levels on cancer cells than target peptide derived from MAGEA4.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Antibody-targeted Amanitin-Conjugate

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Heidelberg Pharma

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement October 22, 2020

            Details:

            ProBioGen is conducting the full service package from cell line development using its CHO.RiGHT® cell line expression platform, incl over process development till GMP manufacturing of the mAb intermediates of Heidelberg Pharma’s ATAC molecules for cancer indications.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): IMA204

            Therapeutic Area: Oncology Product Name: IMA204

            Highest Development Status: Preclinical Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 10, 2020

            Details:

            Two affinity-enhanced TCR candidates designed using Immatics’ proprietary XCEPTOR™ platform demonstrates high specificity and potency; one of the candidates shows full functionality also in CD4+ T cells without requirement for a CD8 co-receptor.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Humanized T-cell therapies

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Versant Ventures

            Deal Size: $78.0 million Upfront Cash: Undisclosed

            Deal Type: Series A Financing August 06, 2020

            Details:

            T-knife’s proprietary humanized mouse platform (HuTCR) T-cell receptors expected to provide superior affinity/specificity properties.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): TUB-010

            Therapeutic Area: Oncology Product Name: TUB-010

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: BioMedPartners

            Deal Size: $12.5 million Upfront Cash: Undisclosed

            Deal Type: Series A Financing July 21, 2020

            Details:

            The funds will be used to accelerate the development of a new class of highly stable and efficient antibody-drug conjugates (ADCs) and to support the further growth of the company.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): RevCAR-T 1

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Intellia Therapeutics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration July 20, 2020

            Details:

            The companies will conduct joint research to combine GEMoaB’s proprietary RevCAR technology platform with Intellia’s proprietary genome editing technologies to discover and develop next-generation allogeneic cellular immunotherapies to treat cancers and inflammatory diseases.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): T cell immunotherapies

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Arya Sciences Acquisition Corp

            Deal Size: $252.0 million Upfront Cash: Undisclosed

            Deal Type: Agreement March 17, 2020

            Details:

            Deal aims at identifying cancer targets and developing the right TCRs for immunotherapies.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): BNT211

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 02, 2020

            Details:

            The data for BNT211 reports Claudin 6 as a novel target for CAR-T cell therapy of solid tumors and introduces CARVac, a new RNA vaccine promoting the amplification of CAR-T cells in vivo.